NIAID Banner Logo Image

HIV Citation List: September 13 - September 26, 2013

PubMed citations

1. Optimization of Diarylazines as anti-HIV Agents with Dramatically Enhanced Solubility.Bollini, M., J.A. Cisneros, K.A. Spasov, K.S. Anderson, and W.L. Jorgensen. Bioorganic & Medicinal Chemistry Letters, 2013. 23(18): p. 5213-5216. PMID[23937980].

[PubMed]. HIV_0913-092613.


2. Structure-guided Discovery of a Novel Aminoglycoside Conjugate Targeting HIV-1 RNA Viral Genome. Ennifar, E., M.W. Aslam, P. Strasser, G. Hoffmann, P. Dumas, and F.L. van Delft. ACS Chemical Biology, 2013. [Epub ahead of print]. PMID[24015986]. .

[PubMed]. HIV_0913-092613.


3. Synthesis and Evaluation of Novel 3-(3,5-Dimethylbenzyl)uracil Analogs as Potential anti-HIV-1 Agents. Sakakibara, N., T. Hamasaki, M. Baba, Y. Demizu, M. Kurihara, K. Irie, M. Iwai, E. Asada, Y. Kato, and T. Maruyama. Bioorganic & Medicinal Chemistry, 2013. 21(18): p. 5900-5906. PMID[23916148].

[PubMed]. HIV_0913-092613.


4. Efficient Convergent Synthesis of Bi-, Tri-, and Tetraantennary Complex Type N-glycans and Their HIV-1 Antigenecity. Shivatare, S.S., S.H. Chang, T.I. Tsai, C.T. Ren, H.Y. Chuang, L. Hsu, C.W. Lin, S.T. Li, C.Y. Wu, and C.H. Wong. Journal of the American Chemical Society, 2013. [Epub ahead of print]. PMID[24032650].

[PubMed]. HIV_0913-092613.


5. Anti-HIV-1 Integrase Activity of Mimusops elengi Leaf Extracts.Suedee, A., S. Tewtrakul, and P. Panichayupakaranant. Pharmaceutical Biology, 2013. [Epub ahead of print]. PMID[24033292].

[PubMed]. HIV_0913-092613.


6. Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex.Tan, Q., Y. Zhu, J. Li, Z. Chen, G.W. Han, I. Kufareva, T. Li, L. Ma, G. Fenalti, J. Li, W. Zhang, X. Xie, H. Yang, H. Jiang, V. Cherezov, H. Liu, R.C. Stevens, Q. Zhao, and B. Wu. Science, 2013. 341(6152): p. 1387-1390. PMID[24030490].

[PubMed]. HIV_0913-092613.

ISI Web of Knowledge Citations

7. Antiretroviral Therapy: Dolutegravir Sets SAIL(ING).Boyd, M.A. and B. Donovan. Lancet, 2013. 382(9893): p. 664-666. ISI[000323542400006].

[WOS]. HIV_0913-092613.


8. Synthesis of a New Series of Biologically Interesting 6 '-Chloro-1',1'-dioxospiro[4H-benzo[D][1,3,7]oxadiazocine-4,3'(2'H)-[1,4,2]benzodithiazine]-2,6(1H,5H)dione Derivatives.Brzozowski, Z., B. Zolnowska, and J. Slawinski. Monatshefte fur Chemie, 2013. 144(9): p. 1397-1405. ISI[000323206000018].

[WOS]. HIV_0913-092613.


9. Heterocyclic HIV-protease Inhibitors.Calugi, C., A. Guarna, and A. Trabocchi. Current Medicinal Chemistry, 2013. 20(30): p. 3693-3710. ISI[000323604600002].

[WOS]. HIV_0913-092613.


10. Protective Role of Anti-viral Human Defensins During Acute HIV Infection.Corleis, B., W. Gostic, and D. Kwon. Journal of Immunology, 2013. 190: 131.25. ISI[000322987104118].

[WOS]. HIV_0913-092613.


11. Harnessing the CRISPR/Cas9 System to Disrupt Latent HIV-1 Provirus.Ebina, H., N. Misawa, Y. Kanemura, and Y. Koyanagi. Scientific Reports, 2013. 3: 2510. ISI[000323474900003].

[WOS]. HIV_0913-092613.


12. Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-density Display of Virus Entry Inhibitors.Farr, C., J.F. Nomellini, E. Ailon, I. Shanina, S. Sangsari, L.A. Cavacini, J. Smit, and M.S. Horwitz. PloS one, 2013. 8(6): p. e65965. ISI[000322361200044].

[WOS]. HIV_0913-092613.


13. Total Synthesis of the Proposed Structure of Didemnaketal B.Fuwa, H., K. Sekine, and M. Sasaki. Organic Letters, 2013. 15(15): p. 3970-3973. ISI[000322853000043].

[WOS]. HIV_0913-092613.


14. Human anti-HIV-1 Envelope Monoclonal Antibodies with a Low Percentage of Mutations Have the Ability to Neutralize Sensitive Tier 1 Viruses.Gorny, M., L.Z. Li, X.H. Wang, C. Williams, B. Volsky, M. Seaman, and S. Zolla-Pazner. Journal of Immunology, 2013. 190: 118.18. ISI[000322987108027].

[WOS]. HIV_0913-092613.


15. N-Methylpyridinium tosylate Catalysed Green Synthesis, X-ray Studies and Antimicrobial Activities of Novel (E)-3-Amino-2-(e)-(3,4-dihydronaphthalen-1(2H)-ylidene)hydrazono)thiazolidin-4-ones. Gupta, R. and R.P. Chaudhary. Phosphorus Sulfur and Silicon and the Related Elements, 2013. 188(9): p. 1296-1304. ISI[000323480900017].

[WOS]. HIV_0913-092613.


16. Synthesis and Biological Activity Evaluation of 5-Pyrazoline Substituted 4-Thiazolidinones. Havrylyuk, D., B. Zimenkovsky, O. Vasylenko, C.W. Day, D.F. Smee, P. Grellier, and R. Lesyk. European Journal of Medicinal Chemistry, 2013. 66: p. 228-237. ISI[000323628500025].

[WOS]. HIV_0913-092613.


17. Structure-based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization.LaLonde, J.M., M. Le-Khac, D.M. Jones, J.R. Courter, J. Park, A. Schon, A.M. Princiotto, X.L. Wu, J.R. Mascola, E. Freire, J. Sodroski, N. Madani, W.A. Hendrickson, and A.B. Smith. ACS Medicinal Chemistry Letters, 2013. 4(3): p. 338-343. ISI[000323593800006].

[WOS]. HIV_0913-092613.


18. Increase of anti-HIV Activity of C-peptide Fusion Inhibitors Using a Bivalent Drug Design Approach. Ling, Y.B., H.F. Xue, X.F. Jiang, L.F. Cai, and K.L. Liu. Bioorganic & Medicinal Chemistry Letters, 2013. 23(17): p. 4770-4773. ISI[000323187000004].

[WOS]. HIV_0913-092613.


19. Design of Cell-permeable Stapled Peptides as HIV-1 Integrase Inhibitors. Long, Y.Q., S.X. Huang, Z. Zawahir, Z.L. Xu, H.Y. Li, T.W. Sanchez, Y. Zhi, S. De Houwer, F. Christ, Z. Debyser, and N. Neamati. Journal of Medicinal Chemistry, 2013. 56(13): p. 5601-5612. ISI[000321884200028].

[WOS]. HIV_0913-092613.


20. Evaluation of the Antimicrobial Activity of Some 4H-Pyrano[3,2-h]quinoline,7H-pyrimido[4',5':6,5]pyrano[3,2-h]quinoline Derivatives.Mohamed, H.M., I.A. Radini, A.M. Al-Ghamdi, and A.M. El-Agrody. Letters in Drug Design & Discovery, 2013. 10(8): p. 758-775. ISI[000323215300013].

[WOS]. HIV_0913-092613.


21. Inhibition of Infection and Transmission of HIV-1 and Lack of Significant Impact on the Vaginal Commensal Lactobacilli by Carbohydrate-binding Agents. Petrova, M.I., L. Mathys, S. Lebeer, S. Noppen, E.J.M. Van Damme, H. Tanaka, Y. Igarashi, M. Vaneechoutte, J. Vanderleyden, and J. Balzarini. Journal of Antimicrobial Chemotherapy, 2013. 68(9): p. 2026-2037. ISI[000323424100013].

[WOS]. HIV_0913-092613.


22. New Solid Forms of the anti-HIV Drug Etravirine: Salts, Cocrystals, and Solubility. Rajput, L., P. Sanphui, and G.R. Desiraju. Crystal Growth & Design, 2013. 13(8): p. 3681-3690. ISI[000323020000052].

[WOS]. HIV_0913-092613.


23. Anti-HIV-1 Integrase Compound from Pometia pinnata Leaves.Suedee, A., S. Tewtrakul, and P. Panichayupakaranant. Pharmaceutical Biology, 2013. 51(10): p. 1256-1261. ISI[000323721200006].

[WOS]. HIV_0913-092613.


24. Macrophage Resistance to HIV-1 Infection Is Enhanced by the Neuropeptides VIP and PACAP. Temerozo, J.R., R. Joaquim, E.G. Regis, W. Savino, and D.C. Bou-Habib. PloS one, 2013. 8(6): p. e67701 . ISI[000322342800143].

[WOS]. HIV_0913-092613.


25. Purification and Characterization of a Protein with Antifungal, Antiproliferative, and HIV-1 Reverse Transcriptase Inhibitory Activities from Small Brown-eyed Cowpea Seeds. Tian, G.T., M.J. Zhu, Y.Y. Wu, Q. Liu, H.X. Wang, and T.B. Ng. Biotechnology and Applied Biochemistry, 2013. 60(4): p. 393-398. ISI[000323378600003].

[WOS]. HIV_0913-092613.

Patent Citations

26. Pyridopyrimidinone Inhibitors of Viruses. Schaus, S.E., L. Brown, J. Connor, and K.W. Dower. Patent. 2013. 2012-US65245 2013115884: 104pp.

[Patent]. HIV_0913-092613.


27. Preparation of Tetrahydro-1,6-naphthyridinylacetic acid Compounds as Inhibitors of Human Immunodeficiency Virus Replication. Walker, M.A., M.E. Sorenson, B.N. Naidu, K. Peese, B.L. Johnson, and M. Patel. Patent. 2013. 2013-766587 20130210857: 37pp.

[Patent]. HIV_0913-092613.


28. Nucleoside Compound with Inhibitory Effect on HIV-1/HBV Viral Replication, Preparation Method and Application in Treating Virus. You, G., H. Liu, and S. Yang. Patent. 2013. 2013-10134492

103232490: 23pp. [Patent]. HIV_0913-092613.


29. A Group of Tenofovir Disoproxil Compounds and and Their Pharmaceutically Acceptable Salts, Their Preparation Method and Application to Antiviral Agent.You, G., H. Liu, and S. Yang. Patent. 2013. 2013-10134160 103224530: 40pp.

[Patent]. HIV_0913-092613.


30. Azasugar-Thiazinone Fuse Ring Derivatives, Synthesis Method and Application in Pharmaceutical Preparation. Li, X., H. Chen, T. Yang, S. Wei, Z. Qin, P. Zhang, and K. Wang. Patent. 2013. 2012-10277577 103275105: 18pp.

[Patent]. HIV_0913-092613.


31. Pyrimidine Derivatives as HIV Inhibitors Useful in Treatment of Diseases Infected by Human Immunodeficiency Virus and Their Preparation.Pendri, A., D.R. Langley, S. Gerritz, G. Li, W. Zhai, S. D'Andrea, M. Patel, B.N. Naidu, K. Peese, and Z. Wang. Patent. 2013. 2013-US28846 2013134113: 114pp.

[Patent]. HIV_0913-092613.


32. Preparation of C3 Cycloalkenyl Triterpenoids with HIV Maturation Inhibitory Activity.Swidorski, J., N.A. Meanwell, A. Regueiro-Ren, S.-Y. Sit, J. Chen, and Y. Chen. Patent. 2013. 2013-US25897 2013123019: 261pp.

[Patent]. HIV_0913-092613.


33. Pyrimidine Derivatives as HIV Replication Inhibitors Useful in Treatment of Diseases Infected by Human Immunodeficiency Virus and Their Preparation.Zheng, Z.B., S. D'Andrea, D.R. Langley, and B.N. Naidu. Patent. 2013. 2013-US28903 2013134142: 63pp.

[Patent]. HIV_0913-092613.

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: September 2022